As per the report published by Fior Markets, The global pharmaceutical contract manufacturing market is expected to grow from USD 92.83 billion in 2017 to USD 150.82 billion by 2025 at a CAGR of 5.35% during the forecast period from 2018-2025. The increasing research activities by biotechnology companies and the rising demand for generics are some of the factors that led to the growth of pharmaceutical contract manufacturing market in North America region.
Global Pharmaceutical Contract Manufacturing Market by Product (API, FDF, Advanced Drug Delivery, OTC Medicines & Nutritional), Application (Pharmaceutical, Biopharmaceutical), End User, Region and Global Forecast 2018-2025.
DOWNLOAD FREE SAMPLE REPORT:https://www.fiormarkets.com/report-detail/375968/request-sample
Prominent companies in the industry include Jubilant Life Sciences Ltd, Catalent Inc., Recipharm AB, Patheon Inc., Boehringer Ingelheim, Pfizer Centresource, Baxter Biopharma Solutions, Aenova, Famar, Lonza, Aesica Pharmaceuticals, Mylan, Vetter Pharma International, Fareva Group are offering greater opportunities and major players are continuously focused on new product developments and venture capital investments to obtain market share. For instance, Catalent Inc. acquired Cook Pharmica LLC. This acquisition strengthened Catalent’s position in biologics development and analytical services and also complements capabilities and expertise in biologic drug development programs.
Product segment covers active pharmaceutical ingredients (API), finished dosage formulations (FDF), advanced drug delivery products, over the counter (OTC) medicines and nutritional products, and others. The finished dosage formulations segment is further divided into tablet, capsule, oral liquids, parenteral/injectables, and others. Active pharmaceutical ingredients (API) segment held highest market share of 27.14% in 2017 due to strong surge in demand especially in generics sector. Application segment pharmaceutical and biopharmaceutical. The pharmaceutical segment valued around USD 53.13 Billion in 2017. The pharmaceutical companies gaining potential profitability in contracting with a CMO (contract manufacturing outsourcing) for both clinical and commercial stage manufacturing has increased the market for the pharmaceutical segment in this market. End user segment includes sterile and non-sterile. Sterile segment is anticipated to grow with highest CAGR 7.01% during the forecast period owing to investments in R&D.
The increasing subcontracting volume by big pharmaceutical companies, expansion in the service offering of complementary metal–oxide–semiconductor (CMOS), and advent of contract development & manufacturing organization (CDMO) model into the market are the key driving factors for the pharmaceutical contract manufacturing market. In addition, growing investment in R&D will lead the growth of pharmaceutical contract manufacturing market in couple of years. The increasing lead time and logistics costs and stringent regulatory requirements may limit the growth of market. Increasing demand for next-generation biological therapies expected to boost the pharmaceutical contract manufacturing market over the forecast period.
Customization of the Report:
This report can be customized to meet the client’s requirements. Please connect with our sales team (firstname.lastname@example.org), who will ensure that you get a report that suits your needs.